Bayer’s Kerendia (finerenone)  had gained approval for usage in managing chronic kidney diseases affiliated with type 2 diabetes two summers ago.

Boehringer Ingelheim GmbH is a pharmaceutical organization that was founded in 1885 and is headquartered in Rheinland-Pfalz, Germany.

Stallerges Greer has disclosed a contract with Nestle regarding the use of Palforzia ® A global agreement to treat peanut allergies.

This article summarized the latest R&D progress of Ketanserin, the Mechanism of Action for Ketanserin, and the drug target R&D trends for Ketanserin.

Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors.

Biogen, Inc. is a biotechnology company based in Cambridge, Massachusetts, USA, specializing in the development of neurological diseases, autoimmune diseases, and cancer drugs.

Comanche Biopharma grants Fast Track Status by FDA for CBP-4888, aimed at treating sFlt-1 induced early-onset preeclampsia

This article summarized the latest R&D progress of Hydroxyprogesterone Caproate, the Mechanism of Action for Hydroxyprogesterone Caproate, and the drug target R&D trends for Hydroxyprogesterone Caproate.

Abata Therapeutics reveals the second development candidate, ABA-201, designed for the management of Type 1 Diabetes

Tumor Necrosis Factor (TNF) is a protein produced by immune cells in the human body. It plays a crucial role in regulating inflammation and immune responses.

BeiGene Ltd. is a global biotechnology company founded in 2010 and is one of China's leading innovative pharmaceutical companies.

AusperBio Therapeutics, Inc.have declared today that the FDA has sanctioned the IND application for testing of AHB-137 in clinics.